LD 1266 requires Maine's Attorney General to form a working group to create a plan expanding access to adult drug, family, and veterans treatment courts statewide. The group must include stakeholders like courts, corrections, health departments, prosecutors, and advocacy organizations to ensure every county has access to these specialty courts for defendants whose criminal involvement relates to substance use disorders. The working group must submit its recommendations and suggested legislation to the Judiciary Committee by January 1, 2026. This resolve does not change current law but directs a study to improve access to treatment-based court options.
LD 380 amends Maine's Address Confidentiality Program to include gender-affirming health care practitioners as eligible participants, expanding the program beyond its prior focus on reproductive health care. This allows practitioners to use a designated address for mail and legal purposes, keeping their personal address confidential to enhance safety. The bill repeals prior provisions that had limited eligibility to reproductive health care practitioners and updates the program to cover both reproductive and gender-affirming services. The change is administrative and does not regulate the provision of health care services.
This bill amends Maine's paid family and medical leave laws to clarify employee leave options and strengthen program administration. It specifies that employees may take leave in hourly increments only if agreed upon with their employer, and creates a dedicated Bureau of Paid Family and Medical Leave within the Department of Labor to manage the program. The bill adds enforcement tools for unpaid employer payments, including civil lawsuits and property levies, and holds successor businesses liable for unpaid premiums from acquired employers. It also establishes fines for employers whose private leave plans lapse during approved substitutions, with collected fines directed to the state fund. These changes primarily affect Maine employers participating in the paid leave program and employees seeking leave benefits.
LD 1154 requires healthcare providers to inform women seeking an abortion for a fetus diagnosed with a lethal fetal anomaly (a condition likely to cause the baby's death within three months after birth) about perinatal hospice services as part of the informed consent process. Providers must discuss these services in person at least 24 hours before the procedure and provide a written list of available perinatal hospice providers, which the state will maintain. If the woman declines hospice services and chooses to proceed with the abortion, she must sign a written certification confirming her decision. This requirement does not apply in cases of medical emergencies or for abortions related to ectopic pregnancy or spontaneous miscarriage.
LD 1007 requires healthcare professionals in Maine to provide specific information during informed consent for drug-induced abortions. It mandates that providers inform patients about the potential for reversal if they change their mind (noting time sensitivity), and that initial studies suggest no increased maternal mortality or birth defect risks from reversal. Providers must also give patients a written statement with a website and helpline number (to be updated annually by the Department of Health) for information on abortion pill reversal services. This bill directly affects women seeking drug-induced abortions and their healthcare providers in Maine.
LD 886 regulates medication abortions in Maine by requiring in-person consultations and prescriptions from licensed health care professionals. It prohibits purchasing or obtaining medication abortion drugs online and mandates that providers explain the process, expected experiences, physical/emotional/spiritual risks, and potential reversal options to patients. The bill directly affects individuals seeking medication abortions and the health care professionals who provide them. These provisions aim to standardize access and information for medication abortions under Maine law.
LD 887 requires health care providers to be physically present during chemical abortions, including examining the patient, scheduling a follow-up within 7 days, and providing a labeled catch kit and medical waste bag for proper disposal. It makes manufacturers of abortion drugs liable for the proper disposal of the drugs and cleanup if endocrine disruptors (chemicals interfering with hormones) are found in wastewater, imposing $20,000 civil penalties for violations. The bill directly affects providers prescribing abortion drugs, manufacturers of these drugs, and patients receiving chemical abortions. Exceptions apply only for life-threatening medical emergencies. This bill does not change the legal status of abortion but adds specific procedural and disposal requirements.
LD 1899 creates a new deduction for Maine state income tax on medical and dental expenses paid by taxpayers or their spouses/dependents. It allows a deduction for expenses that qualify under federal tax law (Internal Revenue Code), even if they don't meet the federal threshold or weren't claimed on federal returns. The deduction applies to expenses not covered by insurance and is effective for tax years beginning January 1, 2026. This directly affects individual Maine taxpayers who pay for healthcare costs, expanding their state tax relief beyond federal requirements.
LD 544 exempts sales of cannabis for medical use from Maine's sales tax, creating tax parity with prescription medicines. The bill amends Maine's tax code to include medical cannabis sales (after January 1, 2026) under the existing exemption for prescription medicines sold by doctors. It directly affects patients certified for medical cannabis use under Maine's Medical Use of Cannabis Act and providers selling to them. This policy change removes a sales tax burden currently applied to medical cannabis, aligning its tax treatment with other prescribed medicines. The exemption applies only to cannabis sold with a medical provider's certification, not recreational sales.
LD 1333 updates Maine's Paid Family and Medical Leave program to clarify eligibility and administration. It requires employees to have worked for an employer for at least 120 days to qualify, shortens the deadline for filing leave applications from 90 to 30 days after leave begins, and adjusts employer contribution rules: companies with 15+ workers can deduct 50% of premiums from employee wages and send 100% to the fund, while smaller employers send 50%. The bill also specifies that leave under this program runs concurrently with federal FMLA, and defines "self-employed" to include small business owners with fewer than 15 employees. These changes directly affect Maine workers seeking leave and their employers managing contributions.
